Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSV | O60911 | 5/20 | 0.65 |
| ▸ | CTSL | P07711 | 5/20 | 0.65 |
| ▸ | EGFR | P00533 | 5/20 | 0.62 |
| ▸ | ERBB2 | P04626 | 4/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.59 |
| ▸ | NPC1 | O15118 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.59 |
| ▸ | HPGD | P15428 | 1/20 | 0.59 |
| ▸ | RAB9A | P51151 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.56 |
| ▸ | PTK6 | Q13882 | 1/20 | 0.54 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.54 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.54 |
| ▸ | CLCN2 | P51788 | 1/20 | 0.54 |
| ▸ | ACP1 | P24666 | 1/20 | 0.53 |
| ▸ | PTPN12 | Q05209 | 1/20 | 0.53 |
| ▸ | PTPN13 | Q12923 | 1/20 | 0.53 |
| ▸ | SSU72 | Q9NP77 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2814761 | 0.87 | MAPT (0.57) | CTSVCTSLEGFRERBB2KDM4E | |
| SCHEMBL10833856 | 0.82 | SIRT2 (0.74) | CTSVCTSLKDM4ENPC1ALDH1A1 | |
| SCHEMBL3975050 | 0.81 | EGFR (0.62) | CTSVCTSLEGFRERBB2HPGD | |
| SCHEMBL3231604 | 0.79 | MRGPRX4 (0.63) | EGFRERBB2KDM4ENPC1ALDH1A1 | |
| SCHEMBL25311091 | 0.79 | MAPT (0.61) | EGFRKDM4EALDH1A1SMN1; SMN2MAPT | |
| SCHEMBL21327265 | 0.79 | ALDH1A1 (0.56) | EGFRERBB2KDM4ENPC1ALDH1A1 | |
| SCHEMBL2294806 | 0.78 | ALDH1A1 (0.66) | KDM4ENPC1ALDH1A1HPGDRAB9A | |
| SCHEMBL1105428 | 0.77 | EGFR (1.00) | EGFRERBB2 | |
| SCHEMBL4565811 | 0.77 | EGFR (0.79) | EGFRERBB2 | |
| SCHEMBL21327080 | 0.77 | POLB (0.58) | CTSVCTSLEGFRERBB2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230357134-A1 | AGENTS FOR USE IN THE TREATMENT OF AMYLOIDOSIS | UCL BUSINESS LTD (GB) | 2023-11-09 | — | — | US | disclosed |
| US-20230357134-A1 | AGENTS FOR USE IN THE TREATMENT OF AMYLOIDOSIS | UCL BUSINESS LTD (GB) | 2023-11-09 | — | — | US | disclosed |
| EP-4214189-A1 | AGENTS FOR USE IN THE TREATMENT OF AMYLOIDOSIS | UCL Business Ltd (GB) | 2023-07-26 | — | — | EP | disclosed |
| WO-2022058733-A1 | AGENTS FOR USE IN THE TREATMENT OF AMYLOIDOSIS | UCL BUSINESS PLC (GB) | 2022-03-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230357134-A1 | AGENTS FOR USE IN THE TREATMENT OF AMYLOIDOSIS | TTR, C1R, APOB | CTSV 199/4885CTSL 143/4885EGFR 782/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.